Citigroup Boosts Insulet (NASDAQ:PODD) Price Target to $275.00

Insulet (NASDAQ:PODD) had its price target increased by equities researchers at Citigroup from $250.00 to $275.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Citigroup’s price target points to a potential upside of 18.54% from the stock’s previous close.

PODD has been the topic of a number of other research reports. Barclays boosted their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Canaccord Genuity Group increased their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. UBS Group increased their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, BTIG Research decreased their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average price target of $234.60.

Insulet Stock Down 0.3 %

Shares of NASDAQ PODD traded down $0.77 during mid-day trading on Tuesday, hitting $231.98. The company had a trading volume of 175,240 shares, compared to its average volume of 822,303. Insulet has a one year low of $125.82 and a one year high of $243.98. The company has a market capitalization of $16.25 billion, a PE ratio of 70.04, a price-to-earnings-growth ratio of 4.47 and a beta of 1.21. The firm has a 50-day simple moving average of $207.58 and a two-hundred day simple moving average of $190.98. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 earnings per share. On average, equities analysts expect that Insulet will post 3.04 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. acquired a new stake in Insulet in the 1st quarter worth approximately $29,000. International Assets Investment Management LLC purchased a new stake in Insulet in the 2nd quarter worth $32,000. UMB Bank n.a. increased its holdings in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Insulet during the fourth quarter worth $40,000. Finally, CVA Family Office LLC grew its holdings in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.